TiumBio Co. Ltd
TiumBio Co., Ltd., a drug discovery company, researches and develops therapeutics for patients with unaddressed rare diseases. The company's products pipeline includes chemical entity-based drugs and biopharmaceuticals comprising NCE401, NCE403, NCE406, and NBP604. It has a collaboration agreement with Oncodesign Société Anonyme for the research and development of fibrosis drug candidates. The co… Read more
Market Cap & Net Worth: TiumBio Co. Ltd (321550)
TiumBio Co. Ltd (KQ:321550) has a market capitalization of $144.60 Million (₩211.73 Billion) as of March 18, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #18517 globally and #683 in its home market, demonstrating a 15.73% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying TiumBio Co. Ltd's stock price ₩7800.00 by its total outstanding shares 27144909 (27.14 Million).
TiumBio Co. Ltd Market Cap History: 2020 to 2026
TiumBio Co. Ltd's market capitalization history from 2020 to 2026. Data shows change from $391.17 Million to $144.60 Million (-9.72% CAGR).
Index Memberships
TiumBio Co. Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$167.85 Billion | 0.06% | #282 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$167.85 Billion | 0.06% | #282 of 1384 |
Weight: TiumBio Co. Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
TiumBio Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how TiumBio Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.01x
TiumBio Co. Ltd's market cap is 0.01 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $391.17 Million | $1.05 Billion | -$12.12 Billion | 0.37x | N/A |
| 2021 | $357.80 Million | $56.80 Million | -$31.64 Billion | 6.30x | N/A |
| 2022 | $233.59 Million | $9.12 Billion | -$29.85 Billion | 0.03x | N/A |
| 2023 | $181.13 Million | $4.90 Billion | -$17.91 Billion | 0.04x | N/A |
| 2024 | $80.00 Million | $6.79 Billion | -$20.64 Billion | 0.01x | N/A |
Competitor Companies of 321550 by Market Capitalization
Companies near TiumBio Co. Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to TiumBio Co. Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
TiumBio Co. Ltd Historical Marketcap From 2020 to 2026
Between 2020 and today, TiumBio Co. Ltd's market cap moved from $391.17 Million to $ 144.60 Million, with a yearly change of -9.72%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩144.60 Million | +30.22% |
| 2025 | ₩111.05 Million | +38.82% |
| 2024 | ₩80.00 Million | -55.83% |
| 2023 | ₩181.13 Million | -22.46% |
| 2022 | ₩233.59 Million | -34.72% |
| 2021 | ₩357.80 Million | -8.53% |
| 2020 | ₩391.17 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of TiumBio Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $144.60 Million USD |
| MoneyControl | $144.60 Million USD |
| MarketWatch | $144.60 Million USD |
| marketcap.company | $144.60 Million USD |
| Reuters | $144.60 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.